20th December 2018

Press Release

Repositive rounds off 2018 with international accolade

by Repositive

International Recognition for Repositive

Repositive, the Cambridge tech start-up on a mission to accelerate cancer drug discovery, is rounding off a successful 2018 by celebrating an international accolade: Repositive has been crowned European Super Angels Club (ESAC) Digital Health Champion 2018. After achieving success in a national pitching event, Fiona Nielsen, Repositive’s CEO and Founder, competed against five finalists from across Europe, out a pool of hundreds of start-ups across Europe to receive the title in Vienna on 29 November.

The award builds on earlier accolades achieved during 2018, including Fiona Nielsen being awarded both ‘highly commended’ CEO of the Year in the Cambridge Independent Science and Technology Awards and included on the 2018 WISE100 list, as well as Repositive being named one of Cambridge’s 130 most influential businesses.

Cancer Models Platform Developments

The recent local, national and international recognition follows the increased attention around the Repositive Cancer Models platform and Translational Oncology Network where Repositive is enabling cancer researchers to find the right cancer model by connecting researchers to the cancer model inventory of Contract Research Organisations (CROs) worldwide.

Cancer Models was developed in response to calls from BioPharma, and the positive reception since its roll-out during 2018 has resulted in accelerated growth for Repositive. The Repositive Cancer Models inventory covers a range of cancer models and associated services, ranging from Patient-Derived Xenograft (PDX) models, to syngeneic models, organoids and the latest technology platforms for immuno-oncology from CROs across the globe. The inventory is set to expand significantly in early 2019.

Via its online platform and Translational Oncology Network, Repositive has rolled out its Personal Shopper Service, which is providing researchers with personalised custom and confidential service for researchers to find the right cancer model across all Repositive partners. The Personal Shopper Service is being offered free of charge for a limited time, until December 31, 2018. The personalised support from the team in locating difficult-to-find cancer models needed for pre-clinical drug discovery has already proven successful: so far, the shopper service has worked with six companies to locate essential cancer models in just a few weeks, rather than the months typically required. In total, 11 Biopharma companies are already using the Repositive Cancer Models platform and services to prepare for their next pre-clinical study.

The growth in Cancer Models has been mirrored in Repositive’s scaling over 2018. The number of employees has nearly tripled to 40, including three new senior hires, plus the establishment of an impressive advisory board. The team has also expanded into new, larger offices twice within 12 months.

CEO Reflects on Incredible 12 Months

Fiona said: “It has been a fast-paced but incredibly rewarding year for Repositive. We have come a long way in 12 months and have made great strides towards our long-term ambition to accelerate cancer drug discovery by removing the barriers that researchers face in accessing essential data, products and services.

“But if we thought 2018 was busy, we can’t wait to see what 2019 has in store! We look forward to ever more partners, like recent additions Cellesce, working with us to list their data, products and services on Cancer Models. We hope to assist more researchers by providing them with the connections, practical support and networking opportunities they need to thrive. And we expect to see our team get bigger, as we speed up oncology research and speed up progress towards benefits for patients.”

The Repositive Team

Cookies on our website

We use cookie to improve your user experience. If you’d like to know more, please refer to our cookies policy page.

Cookies on our website

We use cookie to improve your user experience. If you’d like to know more, please refer to our cookies policy page.